Principle InvestigatorThe idea behind this study is that the cells responsible for relapse in pediatric patients can be eliminated by repurposing a chemotherapy drug, doxorubicin (DXR), as a targeted therapy to restore anti-cancer immunity against minimal residual disease (MRD) and therapy-resistant LSCs while avoiding broad toxicity and the evolution of resistance. Completion of this project is expected to provide durable cures for pediatric patients at risk for relapse and to do so in a manner that does not result in early death related to the therapy itself.cmhprofilesont:personsuffixperson suffixprns:endDateend dateprns:fullNamefull nameprns:grantAwardedBygrant awarded byprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:principalInvestigatorNameprincipal investigator nameprns:sortOrdersort orderprns:startDatestart dateAgreementDepartmentvivo:descriptiondescriptionDivisionGrantvivo:hrJobTitleHR job titlePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofRolevivo:roleContributesTocontributes tordf:typetyperdfs:labellabelAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonPhDJohnPerryJohn M. Perry0.000000000000000.00000000000000123Perry, JohnResearch Faculty PhDPediatricsResearch2021-10-31Braden's HopeJohn M. Perry2018-11-01Overcoming therapeutic resistance by repurposing a classic chemotherapeutic drug as a targeted therapy to reactivate anti-cancer immunityChildren's Mercy Kansas Citytrue1Research Faculty PhDResearch Faculty PhD